The November 2024 Oncology Coding Break, led by Patricia Fordham, focused on refining the accuracy of treatment coding for specific malignancies and conditions. Patricia, a Quality Control Manager at Registry Partners, drew upon her extensive experience conducting abstracting quality reviews to highlight common issues and best practices. This session centered on three key areas: By focusing on these cases, Patricia underscored the importance of precise treatment…

In our quality reviews, we often encounter confusion regarding how to code two SSDI fields for Prostate: Number of Cores Positive and Number of Cores Examined. This confusion typically arises when there is a discrepancy between the pathology report’s final diagnosis and the gross description, or between the dictated physician procedure report and the pathology report. To prevent errors in coding, it is essential to prioritize…

Estrogen and Progesterone percent positive or range is the percentage of cells staining ER or PR positive by IHC. Breast SSDI estrogen receptor (ER) percent positive or range and progesterone receptor (PR) percent positive or range have been collected since 2018. Cancers with these types of receptors are called hormone responsive cancers. Hormone responsive cancer patients will most likely be prescribed treatments that will block estrogen…